+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Results for tag: "RNA Interference"

Oligonucleotide Therapeutics - Global Strategic Business Report - Product Thumbnail Image

Oligonucleotide Therapeutics - Global Strategic Business Report

  • Report
  • August 2025
  • 193 Pages
  • Global
From
From
From
From
From
From
From
From
From
From
From
Innovation Insights: siRNA gene silencing - Product Thumbnail Image

Innovation Insights: siRNA gene silencing

  • Report
  • January 2025
  • 53 Pages
  • Global
From
Innovation Insights: RNA-targeting Small Molecules - Product Thumbnail Image

Innovation Insights: RNA-targeting Small Molecules

  • Report
  • January 2025
  • 48 Pages
  • Global
From
From
Gene Therapy Market Outlook to 2029 - Product Thumbnail Image

Gene Therapy Market Outlook to 2029

  • Report
  • October 2024
  • 83 Pages
  • Global
From
Loading Indicator

RNA interference (RNAi) is a biotechnological process that uses small pieces of double-stranded RNA (dsRNA) to inhibit gene expression. It is a powerful tool for studying gene function and has been used to develop treatments for a variety of diseases. RNAi has been used to target and silence specific genes, allowing researchers to study the effects of gene silencing on cell function. It has also been used to develop treatments for cancer, viral infections, and other diseases. RNAi technology has been used to develop a variety of therapeutics, including small interfering RNAs (siRNAs), microRNAs (miRNAs), and antisense oligonucleotides (ASOs). siRNAs are short pieces of dsRNA that can be used to target and silence specific genes. miRNAs are small pieces of single-stranded RNA that can regulate gene expression. ASOs are short pieces of DNA that can be used to target and silence specific genes. The RNAi market is a rapidly growing segment of the biotechnology industry. Companies in the market include Alnylam Pharmaceuticals, Arrowhead Pharmaceuticals, BioNTech, Editas Medicine, and Moderna Therapeutics. These companies are developing a variety of RNAi-based therapeutics for a range of diseases. Show Less Read more